Literature DB >> 1332541

A method for increasing the yield of properly folded recombinant fusion proteins: single-chain immunotoxins from renaturation of bacterial inclusion bodies.

J Buchner1, I Pastan, U Brinkmann.   

Abstract

Many proteins produced in Escherichia coli accumulate in inclusion bodies. We have systematically evaluated the parameters that affect the refolding and renaturation of enzymatically active molecules from bacterial inclusion bodies containing a recombinant single-chain immunotoxin, B3(Fv)-PE38KDEL. This recombinant molecule is composed of the variable domains of monoclonal antibody B3 (B3(Fv)) fused to a truncated mutant form of Pseudomonas exotoxin A (PE38KDEL). This immunotoxin kills carcinoma cells in vitro, causes tumor regression in animal tumor models, and is being developed as an anti-cancer therapeutic agent (Brinkmann et al., 1991, Proc. Natl. Acad. Sci. USA 88, 8616-8620). Like many other recombinant proteins, B3(Fv)-PE38KDEL is produced in E. coli in inclusion bodies and must be denatured and refolded to become active. This requires correct folding, formation of native disulfide bonds, and the association of different domains. All these steps are strongly dependent on the renaturation conditions used. Optimum conditions of refolding were obtained by the addition of reduced and oxidized thiol reagents to promote disulfide bond formation and the addition of a labilizing agent such as L-arginine. Furthermore, the necessity to reactivate proteins at low protein concentrations due to its tendency to aggregate at high concentrations was overcome by a step-by-step addition of denatured and reduced protein into the refolding solution. This approach should be useful for the production of active forms of other recombinant proteins.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1332541     DOI: 10.1016/0003-2697(92)90433-8

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.191


  61 in total

Review 1.  Generation of recombinant antibodies.

Authors:  S M Kipriyanov; M Little
Journal:  Mol Biotechnol       Date:  1999-09       Impact factor: 2.695

Review 2.  Immunotoxins for targeted cancer therapy.

Authors:  Robert J Kreitman
Journal:  AAPS J       Date:  2006-08-18       Impact factor: 4.009

3.  Incorporating an allosteric regulatory site in an antibody through backbone design.

Authors:  Olga Khersonsky; Sarel J Fleishman
Journal:  Protein Sci       Date:  2017-03-06       Impact factor: 6.725

Review 4.  Production of active eukaryotic proteins through bacterial expression systems: a review of the existing biotechnology strategies.

Authors:  Sudhir Sahdev; Sunil K Khattar; Kulvinder Singh Saini
Journal:  Mol Cell Biochem       Date:  2007-09-12       Impact factor: 3.396

5.  Chemokine receptor targeting efficiently directs antigens to MHC class I pathways and elicits antigen-specific CD8+ T-cell responses.

Authors:  Roberta Schiavo; Dolgor Baatar; Purevdorj Olkhanud; Fred E Indig; Nicholas Restifo; Dennis Taub; Arya Biragyn
Journal:  Blood       Date:  2006-03-02       Impact factor: 22.113

6.  NMR studies of the dynamics of nitrophorin 2 bound to nitric oxide.

Authors:  Dhanasekaran Muthu; Robert E Berry; Hongjun Zhang; F Ann Walker
Journal:  Biochemistry       Date:  2013-10-30       Impact factor: 3.162

7.  "Inclonals": IgGs and IgG-enzyme fusion proteins produced in an E. coli expression-refolding system.

Authors:  Rahely Hakim; Itai Benhar
Journal:  MAbs       Date:  2009-05-19       Impact factor: 5.857

8.  Optimized Procedure for Recovering HIV-1 Protease (C-SA) from Inclusion Bodies.

Authors:  Sibusiso B Maseko; Deidre Govender; Thavendran Govender; Tricia Naicker; Johnson Lin; Glenn E M Maguire; Hendrik G Kruger
Journal:  Protein J       Date:  2019-02       Impact factor: 2.371

9.  Modification in media composition to obtain secretory production of STxB-based vaccines using Escherichia coli.

Authors:  Mohammad Sadraeian; Mohammad Bagher Ghoshoon; Milad Mohkam; Zeinab Karimi; Sara Rasoul-Amini; Younes Ghasemi
Journal:  Virol Sin       Date:  2013-01-17       Impact factor: 4.327

10.  Essential role for Bim in mediating the apoptotic and antitumor activities of immunotoxins.

Authors:  A Antignani; D Segal; N Simon; R J Kreitman; D Huang; D J FitzGerald
Journal:  Oncogene       Date:  2017-04-24       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.